Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-03-31
2010-06-22
Kumar, Shailendra (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S522000, C514S524000, C514S616000, C514S620000
Reexamination Certificate
active
07741371
ABSTRACT:
This invention provides a class of androgen receptor targeting agents (ARTA). The compounds are selective androgen receptor modulators (SARM) useful for, inter-alia, suppressing spermatogenesis, treating a subject having a hormone related condition, treating a subject suffering from prostate cancer, delaying the progression of prostate cancer, preventing the recurrence of prostate cancer, and treating the recurrence of prostate cancer.
REFERENCES:
patent: 3875229 (1975-04-01), Gold
patent: 4139638 (1979-02-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4239776 (1980-12-01), Glen et al.
patent: 4282218 (1981-08-01), Glen et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4465507 (1984-08-01), Konno et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4880839 (1989-11-01), Tucker
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5609849 (1997-03-01), Kung
patent: 5656651 (1997-08-01), Sovak et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 6071957 (2000-06-01), Miller et al.
patent: 6160011 (2000-12-01), Miller et al.
patent: 6482861 (2002-11-01), Miller et al.
patent: 6492554 (2002-12-01), Dalton et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 7022870 (2006-04-01), Dalton et al.
patent: 0040932 (1981-12-01), None
patent: 0100172 (1984-02-01), None
patent: 0002892 (1985-02-01), None
patent: 0253503 (1988-01-01), None
patent: 1360001 (1970-03-01), None
patent: 52-128329 (1977-10-01), None
patent: 54-63047 (1980-12-01), None
patent: WO9519770 (1995-07-01), None
patent: WO9805962 (1998-02-01), None
patent: WO9853826 (1998-12-01), None
patent: WO9855153 (1998-12-01), None
patent: WO0127622 (2001-04-01), None
patent: WO0128990 (2001-04-01), None
patent: WO0134563 (2001-05-01), None
patent: WO0200617 (2002-01-01), None
patent: WO0216310 (2002-02-01), None
U.S. Appl. No. 10/298,229, filed Nov. 28, 2002, Miller, et al.
U.S. Appl. No. 10/270,232, filed Oct. 15, 2002, Dalton, et al.
U.S. Appl. No. 10/277,108, filed Oct. 23, 2002, Dalton, et al.
U.S. Appl. No. 10/270,233, filed Oct. 15, 2002, Dalton, et al.
U.S. Appl. No. 10/270,732, filed Oct. 15, 2002, Dalton, et al.
U.S. Appl. No. 10/310,150, filed Dec. 5, 2002, Steiner, et al.
Eliason, et al (2002) “High Throughput Fluorescence Polarazation-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands.” Abstracts of Papers, 223rdACS National Meeting, Orlando, FL, U.S.
Tucker, et al (1988) “Resolution of the Nonsteroidal Antiandrogen—4′-Cyano-3-[(4-flurophenyl) solfonyl1]—2-hydroxy-2 methyl-3′-(trifluromythyl1)—propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer:” J Med Chem 31, 885-887.
Mckillop, et al (1995) “Enantioselective metabolism and pharmacokinetics of Casodex in the male rat” vol. 25, No. 6, 623-634.
Kirkovsky, et al (1997) “[125l]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer” Poster Presentation MEDI 155, 214thACS National Meeting Las Vegas. NV, Sep. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38183.
Baird, et al (1993) “Hormonal Contraception—Drug Therapy”, The New England Journal of Medicine, 1543-1549.
F.C. W. Wu (1988) “Male Contraception: Current Status and Future Prospects”, Clinical Endocrinology , 29, 443-465.
Djerassi, et al “A new look at male contraception”, Nature, vol. 370 11-12.
World Health Organization Task Force on Methods for the Regulation of Male Fertility, (1990) “Contracepive efficacy of testosterone-induced azoospermia in normal men”. The Lancet, vol. 338, 955-959 and 1517-1518.
Francisco, et al (1990) “Long-acting contraceptive agents: testosterone esters of unsaturated acides”, Steroids, vol. 55 Butterworths.
Hoberman, et al (1995) “The History of Synthetic Testosterone” Scientific American 76-81.
Kirkovsky, et al (1995) “Approaches to Irreversible non-steroidal chiral antiandrogens” Department of Pharmaceutical Sciences, University of Tennessee 47thSoutheast/51stSouthwest Joint Regional Meeting of the American Chemical Society, Memphis, TN.
Handelsman (1996) “Bridging the Gender Gap in Contraception: another hurldle cleared” The Medical Journal of Australia vol. 154, 230-233.
Edwards JP, et al (1999) Nonsteriodal androgen receptor agonists based on 4-(trifluromythyl1)-2H-pyrano [3, 2-g] quinolin-2-one Bioorg Med. Chem. Lett.9:1003.
Zhi L, et al (1999) Switching androgen receptor antiagonists to agonists by modifying C-ring substituents on piperidino [3,2-g]quinolone. Bioorg Med Chem. Lett. 1009.
Higuchi, et al (1999) 4-Alkyl—and 3,4-diakly1-1,2,3,4-tetrhydro-8-pyridono(5,6-g) quinolines: potent, nonsteriodal, androgen receptor agonists Bioorg. Med. Chem. Lett. 9:1335.
Hamann, et al (1999) Discovery of a potent, orally active nonsteriodal androgen receptor against: 4-ethyl-1, 2. 3, 4-tetrahydro-6-(trifluoromethyl)-8pyridono[5,6-g]-quinoline (LG121071). J Med Chem. 42: 210.
Rosen, et al (1995) Intracellular receptors and signal transducers and activators of transcription super families: novel targets for small-molecuile drug discovery. J Med. Chem. 38:4855.
Dalton, et al (1998) “Discovery of Nonsteroidal Androgens” Biochem Biophys Res Commun 244(1):l-4.
Edwards, et al (1998) New nonsteroidal androgen receptor modulators based on 4-(trifluromythyl)-2-(1H)-Pyrololidino[3,2-g]quinolone. Bioord Med Chem. Lett. 8:745.
Berger, et al (1975) “Concepts and Limitations in the application of radiolabled antiandrogens, estrogens, or androgens as isotropic scanning agents for the prostate” Invest. Urol 1391, 10-16.
Corey (1987) “Asymmetric Bromolactonization Reaction: Synthesis of Optically Active 2-Hydroxy-2-Methylalkanoic Acids from 2-Methylenealkanoic Acids” Tetrahedron Letters vol. 28, No. 25, 2801-2804.
Dalton James T.
Gao Wenqing
Marhefka Craig A.
Miller Duane D.
Cohen Mark S.
Kumar Shailendra
Pearl Cohen Zedek Latzer LLP
University of Tennessee Research Foundation
LandOfFree
Selective androgen receptor modulators and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective androgen receptor modulators and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective androgen receptor modulators and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175326